About this trial
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
Patient Profile
For Patients with Advanced Renal Cell Carcinoma (RCC) with clear cell component after prior therapy
Where’s this trial being run?
Tallaght University Hospital, Mater Misericordiae University Hospital, and Mater Private Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK6482-011 |
|---|---|
| Number: | 21-17 |
| Full Title: | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy |
| Principal Investigator: | Prof. Ray McDermott |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Merck Sharp & Dohme LLC |
| Recruitment Started: |
Global: 25-Feb-2021 Ireland: 09-Dec-2021 |
| Global Recruitment Target: | |
|---|---|
| Ireland Recruitment Target: | 8 |